close

Subscribe to our dermatology newsletter

SIGN ME UP 

Fungal skin infections

Acknowledgements

Developed in collaboration with the University of Auckland Goodfellow Unit in 2007.

Author: Hon A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand, 2009.  

Images have been sourced from the following:

  • Hon Assoc Prof Amanda Oakley
  • The Department of Dermatology, Health Waikato
  • Prof Raimo Suhonen (Finland)

 goodfellow unit logo

Oral antifungal drugs CME

Previous

Created 2009.

Learning objectives

Introduction

Oral antifungal drugs currently in use include itraconazole, fluconazole, ketoconazole and terbinafine. They are reserved for extensive or severe infection for which topical antifungal agents are inappropriate or ineffective, because of high cost, potential side effects and drug interactions. Griseofulvin is not discussed as it is no longer available in New Zealand. Nor is nystatin, as it is only appropriate for intestinal candidiasis. Voriconazole has recently become available but is reserve for the treatment of serious and refractory fungal infections in hospitalised patients.

Itraconazole

Oral itraconazole (Sporanox™) is a very useful broad spectrum antifungal drug. It should be taken after a fatty meal, preferably with an acidic drink such as orange juice.

Dosing regimes depend on the skin condition, its duration and severity, and need for prophylaxis. For example:

Nausea is the most common side effect. Abnormal liver function tests affect 5% of those on long term therapy but are rarely severe (monitoring is recommended for prolonged courses). It has been reported to cause congestive cardiac failure and serious rashes. The main concern with azoles is serious interactions with other medications.

As itraconazole needs acid for its absorption, antacids, H2 antagonists and omeprazole should not be taken for 2 hours after itraconazole.

These drugs should not be taken by those on itraconazole:

The dose of these drugs should be reduced:

The dose of these drugs may need reducing if side effects arise:

The following drugs decrease the concentration of itraconazole:

Itraconazole is not thought to interact with the oral contraceptive pill and must be avoided in pregnancy.

Fluconazole

Fluconazole (Diflucan™) is a triazole used for candidiasis and cutaneous dermatophyte infections. It is not registered for nail infections. The dose and duration depends on the nature and severity of infection. Typically:

The main contraindication is concomitant administration with cisapride. It should be avoided in pregnancy / lactation and in the presence of electrolyte abnormalities, heart disease and renal impairment.

Side effects include:

Drug interactions are similar to those for itraconazole. Refer to a current prescribing text.

Ketoconazole

Ketoconazole (Nizoral™) is used to treat fungal infections where other treatments have failed or are contraindicated. It is effective for yeasts and dermatophytes and is usually prescribed in a daily dose of 200mg after food.

Its main concern is hepatic – liver function should be monitored. The incidence of significant hepatitis is about 1:1500, much higher than with itraconazole. It has similar interactions with other drugs.

Terbinafine

Terbinafine can be taken with or without food. Listed side effects include:

Drug interactions are not as frequent or as serious as with itraconazole. However, interactions are reported with tricyclic antidepressants, beta-blockers, SSRIa, MAOIs, hepatic enzyme inhibitors (cimetidine) or inducers (rifampicin) and possibly with oral contraceptives.

Activity

Refer to your local laboratory data, MIMS NZ and/or PHARMAC Pharmaceutical schedule. Find out the cost to treat an uncomplicated case of onychomycosis effectively.

Related information

Previous  

Email Newsletter

Would you like to receive our dermatology updates by email?

SIGN UP

Submit your images

We're seeking high-quality photos of skin diseases.  

SUBMIT A PHOTO

Skin lesion photography

Watch Dr Amanda Oakley presenting "Skin lesion photography" at The Australasian Skin Cancer Congress.

Subscribe to our mailing list

* indicates required
DermNet NZ Newsletter